Zentalis Pharmaceuticals, INC 10-Q quarterly reports

Zentalis Pharmaceuticals reports Q1 2026 results, with a focus on advancing azenosertib clinical trials and managing cash runway.

Zentalis Pharmaceuticals reports reduced net losses and extended cash runway into late 2027, driven by strategic restructuring and ongoing clinical development of azenosertib for ovarian cancer.

Zentalis Pharmaceuticals reports reduced net losses and extended cash runway into late 2027, driven by strategic restructuring and progress in its lead ovarian cancer drug, azenosertib.

Zentalis Pharmaceuticals announces its Q1 2025 financial results and provides an update on the clinical development of its lead drug candidate, azenosertib, focusing on Cyclin E1+ PROC.

Zentalis Pharmaceuticals reported a net loss of $118.4 million for the first nine months of 2024, while highlighting progress in its azenosertib clinical development program.

Zentalis Pharmaceuticals reports a net loss of $78.2 million for the first half of 2024, while also providing updates on its clinical programs, including a partial clinical hold on certain azenosertib trials.

Zentalis Pharmaceuticals reported a net income of $10.0 million for the first quarter of 2024, primarily driven by a significant licensing agreement.